- Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in November
- For the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to 12.0% of individuals treated with vehicle (P
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
On 6ix: 6ix.com/news/arcutis-announces-positive-topline-results-from-second-atopic-dermatitis-pivotal
Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Replay · Nov 4Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings CallArcutis Biotherapeutics, Inc. on 6ix
Story so far
- Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
- Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Earlier from Arcutis Biotherapeutics
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
- Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
- Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
- Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Later from Arcutis Biotherapeutics
- Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
- Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
- Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
- Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
- Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Follow Arcutis Biotherapeutics into a list and get an email when it puts out news.
Follow Arcutis Biotherapeutics